In this month’s episode of The Chain, Greg M. Thurber, associate professor of chemical engineering and biomedical engineering at the University of Michigan, sits with moderator Nimish Gera, vice president of biologics at Mythic Therapeutics, to talk about the development of antibody drug conjugates (ADCs). Thurber details the history of ADCs and the skepticism facing the field during the mid-2010s, despite showing great promise in anticancer treatment. He also discusses how recent FDA approvals and breakthroughs have reignited interest and pivoted research toward designing more successful ADCs. Finally, he shares his thoughts on the exciting developments in the field in the next few years, including how ADCs could play a key role in polytherapy.